Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
about
HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment StrategiesAdvanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approachesAdvancements in the Management of HPV-Associated Head and Neck Squamous Cell CarcinomaTargeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for TherapyThe current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neckCIViC databasePrognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or ..Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer.A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategiesAntiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck.Molecular profiling of head and neck squamous cell carcinoma.National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database.Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.Emerging biomarkers in head and neck cancer in the era of genomics.Using a semi-conductor sequencing-based panel for genotyping of HPV-positive and HPV-negative oropharyngeal cancer: a retrospective pilot study.Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study.p16, HPV, and Cetuximab: What Is the Evidence?Current Role of Dacomitinib in Head and Neck Cancer.Challenges in establishing the diagnosis of human papillomavirus-related oropharyngeal carcinoma.Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.Human Papillomavirus (HPV): A Criterion for Therapeutic Decision in Squamous Cell Carcinoma of the Head and Neck?Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC.Treatment de-intensification strategies for head and neck cancer.Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma.The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma.Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.Disease-free survival after salvage therapy for recurrent oropharyngeal squamous cell carcinoma.Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma.Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck.Emerging drugs for head and neck cancer.Emerging insights into recurrent and metastatic human papillomavirus‐related oropharyngeal squamous cell carcinoma.Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
P2860
Q26752584-D01E842E-661B-49ED-A80E-9EAA42C35EE2Q26767046-1F8F80A4-09BE-4846-A413-F35584BE3A54Q26799543-08B12F30-7E37-400E-B940-F38345792909Q26824925-426978EB-4E9B-4ABE-90C3-E74BC35BC177Q26830495-A1605E33-ECB2-440B-9F7F-D981EDDE800FQ27612411-FCFC6874-7BE5-4F01-99E8-436E4D1C657FQ27853003-2EDCE7BD-2112-4054-BFE5-76D9C253F6A1Q27853302-7A15FAB4-EFE8-4E17-8961-6197B658BFE5Q33434648-B4770839-7B62-4DBD-9CF9-807C2A7C55A5Q34957320-1FCF48C9-B1EC-4E53-BF59-462BAA8A54FDQ35688621-54020EBC-3D2E-4989-A14F-145F700EE561Q35693308-9727AF82-51D7-4A2B-871B-9112DFEFB0FEQ35838231-5855DCFE-7C72-4676-AAB9-459C1A6513A1Q36072292-3BF06C84-0011-4B9C-97FB-7AB75E320429Q37337359-C5C5AA7D-38AE-4A0B-B37A-AFC4D92311E4Q37441503-C67766F1-B3A6-4780-A362-56F74BB25EEAQ38240998-3F45C0DD-DB7D-488B-AA42-DD0F538A5186Q38268896-DFAA6EF2-A0C1-4E17-BAEB-8DCEA80A8D9BQ38377139-C5400337-796B-4C4F-A4D5-9FB31D115459Q38583292-ADEE7165-E7AA-4CA2-A7C6-08F28CCBD8E8Q38637666-FFD93DE6-B3A0-45F9-AE28-E683E375819DQ38773776-13FAAE62-B50A-44C1-AA36-02C09F37C03BQ38806115-2AE71F8A-1152-4EFE-A310-41E76F27DB98Q38807472-4AAFF2EA-FC9B-4A14-9A44-23AD829CA56DQ38838071-80ECE5EA-CF27-4FCB-94C4-CCD235C8FD36Q38851239-5D42CA59-F7A5-44F5-BF20-29908DC591F1Q38892486-78117CB2-C9E6-479B-87A7-C44E45084457Q38971554-57DB88BC-97A3-476B-93F9-754A25AA2C9BQ38971558-C6DBDBF8-477C-4A8A-B759-E7D49AED35A2Q38984523-DE2C66E1-815E-41FB-BE57-93B3BB69ACDFQ40046181-2B338CD9-63A8-41FF-ABAE-BA19FA88AC5DQ40081693-29B7789D-B42A-4AA0-B256-CB752BAEC798Q40103314-3F0F64D4-1E57-4539-AEFF-3716FDB7CB70Q40129971-642A275D-2CC8-4212-B014-86F961A292AFQ41132101-F37A937C-F499-479B-A464-034555B17054Q41605972-ACAEB0CE-4C02-4B3D-B8AC-2C1592408B95Q43130011-91B73B4B-2D66-45AE-9198-ABB5F4F38169Q45874449-BA21D908-E262-4DC4-9367-6B094206A71BQ46699165-DC82705A-5B3C-4D38-A506-E8ADD9257090Q46738588-56C1F8EF-054D-44A9-8E3A-BCB1A7218DB2
P2860
Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Impact of tumor HPV status on ...... f the phase III EXTREME trial.
@ast
Impact of tumor HPV status on ...... f the phase III EXTREME trial.
@en
Impact of tumor HPV status on ...... f the phase III EXTREME trial.
@nl
type
label
Impact of tumor HPV status on ...... f the phase III EXTREME trial.
@ast
Impact of tumor HPV status on ...... f the phase III EXTREME trial.
@en
Impact of tumor HPV status on ...... f the phase III EXTREME trial.
@nl
altLabel
Impact of tumor HPV status on ...... of the phase III EXTREME trial
@en
prefLabel
Impact of tumor HPV status on ...... f the phase III EXTREME trial.
@ast
Impact of tumor HPV status on ...... f the phase III EXTREME trial.
@en
Impact of tumor HPV status on ...... f the phase III EXTREME trial.
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Impact of tumor HPV status on ...... f the phase III EXTREME trial.
@en
P2093
J B Vermorken
P2860
P304
P3181
P356
10.1093/ANNONC/MDT574
P50
P577
2014-04-01T00:00:00Z